ArticleDiabetology & metabolic syndrome2025
The effect of virgin coconut oil (VCO) on cardiovascular disease risk factors: a systematic review and meta-analysis.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiometabolic disorders remain a leading cause of morbidity and mortality worldwide. Virgin coconut oil (VCO), rich in medium-chain triglycerides and phenolic compounds, has been proposed to confer metabolic benefits through lipid modulation, anti-inflammatory activity, and antioxidant effects. However, clinical evidence on its efficacy is mixed. This systematic review and meta-analysis evaluated the impact of VCO on key cardiometabolic risk factors in adults.
methodsA comprehensive literature search was conducted in five database from inception to August 2025. RCTs assessing VCO supplementation in adults were included if they reported anthropometric indices, lipid profiles, glycemic markers, blood pressure, or inflammatory outcomes. Data were pooled using a random-effects model.
resultsFourteen RCTs with 1049 participants from 11 countries, with intervention durations ranging from 2 to 24 weeks, met inclusion criteria. Pooled analyses showed that VCO significantly reduced triglycerides (WMD: - 12.12 mg/dL; 95% CI: - 23.14 to - 1.09) and increased high density lipoprotein-cholesterol (HDL-C) (WMD: 7.91 mg/dL; 95% CI: 4.41 to 11.40). No significant changes were observed for other lipid markers, fasting blood sugar (FBS), anthropometric measures, blood pressure, or CRP. Subgroup analyses indicated greater TG reduction in short-term interventions (≤ 8 weeks) and among individuals with metabolic disorders, and a significant TC increase in participants under 50 years. Assessment of publication bias using funnel plots and Egger's test indicated no significant evidence of bias.
conclusionsVCO supplementation may improve specific lipid parameters, particularly TG and HDL-C, while showing limited effects on other cardiometabolic outcomes. Larger, longer-term trials are warranted to clarify its role in cardiometabolic risk management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.